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Abstract 
 
Information on exposure to, and health effects of, cardiovascular disease (CVD) risk factors 
is needed to develop effective strategies to prevent CVD events and deaths. Here, we provide 
an overview of the data and evidence on worldwide exposures to CVD risk factors and the 
associated health effects. Global comparative risk assessment (CRA) studies have estimated 
that hundreds of thousands or millions of CVD deaths are attributable to established CVD 
risk factors (high blood pressure and serum cholesterol, smoking, and high blood glucose), 
high body mass index (BMI), harmful alcohol use, some dietary and environmental 
exposures, and physical inactivity. The established risk factors plus BMI are collectively 
responsible for about 9.7 million annual CVD deaths, with high blood pressure accounting 
for more CVD deaths than any other risk factor. Age-standardized CVD death rates 
attributable to established risk factors plus high BMI are lowest in high-income countries, 
followed by Latin America and the Caribbean; they are highest in the region of central and 
eastern Europe and central Asia. However, estimates of the health effects of CVD risk factors 
are highly uncertain because there are insufficient population-based data on exposure to most 
CVD risk factors and because the magnitudes of their effects on CVDs in observational 
studies are likely to be biased. We identify directions for research and surveillance to better 
estimate the effects of CVD risk factors, and policy options for reducing CVD burden by 
modifying preventable risk factors.  
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Introduction 
Ischemic heart disease (IHD), stroke, and other cardiovascular diseases (CVDs) are 
responsible for an estimated 17.5 million deaths worldwide per year, although the estimates 
of their burden vary across studies due to differences in data sources and methods.1, 2 Further, 
as data and methods evolve, estimates are revised and refined, even for prior years. 
 
In high-income Asian and western countries, where reliable historical data on mortality and 
cause of death are available, age-standardized CVD death rates have steadily decreased for 
decades, with no sign of slowing down.3 Similar trends are happening in Latin America and 
some other middle-income countries with more recent reliable data.3 As a result of these 
trends, age-standardized CVD death rates are now higher in low- and middle-income 
countries than in high-income nations.4 Nonetheless, in high-income countries, population 
growth and ageing may increase the absolute burden of CVDs or lead to slower decline in 
their absolute burden than would be anticipated from the trends in age-standardized death 
rates.5 There is, therefore, an imperative throughout the world to prevent CVD events and 
deaths by reducing exposure to their preventable risk factors.  
 
As an important step towards reducing the worldwide burden of CVDs and other Non-
Communicable Diseases (NCDs), the United Nations held a High-Level Meeting on the 
Prevention and Control of NCDs. Subsequently, countries agreed to reduce premature 
mortality from the four main NCDs (CVDs, chronic respiratory diseases, cancers, and 
diabetes) by 25% relative to its 2010 level by 2025 (known as the 25×25 target).5 Countries 
also agreed on targets for selected NCD risk factors, all of which are associated with CVDs: 
tobacco use, harmful alcohol use, excessive salt intake, obesity, raised blood pressure, raised 
blood glucose and diabetes, and physical inactivity.5 Therefore, there is unprecedented 
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interest in having better information on exposure to, and health effects of, CVD risk factors 
throughout the world. 
 
To respond to this interest, researchers have attempted to quantify the worldwide effects of 
preventable risk factors on CVDs and other conditions for at least two decades. One of the 
first such studies estimated deaths from CVDs and other diseases due to smoking in so-called 
developed countries (Australia and New Zealand, Europe, Japan, and north America).6 
Around the same time, the Global Burden of Disease 1990 Study quantified the health effects 
of ten risk factors,7 including some CVD risk factors like smoking and hypertension, 
although its results were not disaggregated by disease. The Comparative Risk Assessment 
(CRA) Study enhanced consistency and comparability in the methods used for analyzing 
various risks.8 The results of the CRA study also formed the core material for the World 
Health Report 2002: Reducing Risks, Promoting Healthy Life. The CRA Study included 26 
risk factors, about one third of which were associated with CVDs.8, 9 The CRA Study showed 
that CVD risk factors such as elevated blood pressure and smoking were among leading 
causes of mortality and morbidity in the world, with a large share of their health burden borne 
by low- and middle-income countries.8-10 The study also quantified the combined (joint) 
burden of multiple risk factors, accounting for the overlaps among their effects. The joint 
effect analysis showed that nearly 80% of deaths from IHD and nearly 70% of deaths from 
stroke in the world were attributable to a small number of physiological and behavioral risk 
factors including high blood pressure, high serum cholesterol, smoking, high body mass 
index (BMI), alcohol use, low intake of fruits and vegetables, and physical inactivity.11  
 
A number of studies in the past decade have updated the CRA Study analyses or have 
extended the analysis to national and subnational levels.12-18 The list of CVD risk factors in 
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these global and national analyses has expanded to more than sixty, and includes additional 
physiological (e.g., raised blood glucose), dietary, behavioral, and environmental risks.  
 
Here, we use the global analyses of CVD risk factors to provide an overview of current data 
on their exposures and the associated health effects throughout the world (we do not cover 
temporal trends in CVD risk factors or their within-country social inequalities, because these 
topics have been addressed in other recent reviews).3, 4, 19 With rapid expansion of clinical 
and epidemiological studies about the etiology and predictors of CVDs, there is an evolving 
list of putative CVD risk factors, with evidence of causality ranging from very strong to 
inconclusive and non-compelling.20, 21 Therefore, we first present a simple framework that 
can guide the selection of risk factors for global or national analyses. We then present the 
current evidence on exposure to, and health effects of, different clusters of risk factors, 
including established risk factors (smoking, raised blood pressure, diabetes, and raised serum 
cholesterol) and excess weight and adiposity; alcohol use; diet; physical inactivity; 
environmental risks; and other putative (emerging) risk factors which are the subject of 
extensive research. Based on limitations and uncertainties in the current data, we suggest 
future directions for research and surveillance. We also discuss the implications of current 
knowledge for global CVD prevention.  
 
A framework for selecting CVD risk factors for global analyses 
A first step in quantifying the national and global effects of risk factors on CVDs is the 
selection of relevant risk factors. The inclusion of a factor implies that it is a cause of CVDs 
or a strong proxy marker for causal factors. To illustrate the types of factors that may be 
included, Figure 1 provides a simple representation of CVD risk factors, both those that are 
more distant from clinical outcomes (e.g., the social environment) and those more proximate 
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to these outcomes (e.g., high blood pressure). The physiological factors, which mediate the 
effects of more distal ones, may be modified either through changes in their behavioral and 
environmental determinants or through medicines used for primary and secondary 
prevention. Other factors in Figure 1 – which may be both genetic and non-genetic, e.g. 
prenatal and early life nutrition and environment – affect susceptibility and predisposition to 
CVDs. Prenatal and early life nutrition may affect current and future CVD burden, and be a 
also modifier of the CVD burden attributable to other exposures, but to date there has been 
little attempt to quantify its role at the population level. 
 
Many of the factors depicted in Figure 1 have been associated with CVDs in observational 
studies. However, confounding and residual confounding could lead to apparent associations 
with CVDs that might not represent genuine causal effects or can bias the magnitudes of 
associations, a problem that is exacerbated by selective reporting and publication bias.22-25 
For this reason, we state throughout the paper when the associations between risk factors and 
CVDs in observational studies are also supported by randomized trials and/or Mendelian 
randomization studies. Mendelian randomization takes advantage of lifelong differences in 
risk factor levels due to genetic variants and is hence not confounded by lifestyle factors.26-28 
As a result, Mendelian randomization studies can shed light on the causality of associations 
and rule out confounding due to unmeasured factors or reverse causation. For example, 
Mendelian randomization analysis has helped confirm the role of height, a trait that is 
difficult to study in a randomized trial, as a CVD risk factor.29 It has also helped rule out a 
causal role for C-reactive protein as a CVD risk factor.30, 31 However, Mendelian 
randomization is affected by several other limitations including the assumption of a simple 
model of causality without genetic pleiotropy (i.e., when one gene influences disease risk 
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through multiple pathways). Further, it only provides indirect information on the magnitude 
of causal effects which is needed for robust quantification of the CVD burden of risk factors.  
 
The diversity of risk factors for CVDs, and the fact that the effects of upstream factors are 
partially mediated through those more proximate to clinical outcomes, also means that the 
CVD burden attributable to individual factors cannot be added.11 Rather, the combined CVD 
burden of multiple factors is often smaller than the sum of individual ones;11, 32 its calculation 
requires quantitative information on their interactions,33 and on the extent of mediation.34 As 
described earlier, the original CRA Study calculated the individual and combined effects of 
high blood pressure, high serum cholesterol, smoking, high BMI, alcohol use, low intake of 
fruits and vegetables, and physical inactivity.11 The results showed that nearly 80% of deaths 
from IHD and nearly 70% of deaths from stroke in the world were attributable to the 
combined effects of these risk factors whereas the sum of their individual effects were 226% 
for IHD and 165% for stroke. We present the combined effects of established risk factors and 
high BMI below, using more recent epidemiological evidence.14, 34 
 
Established risk factors and adiposity 
Causal effects of established risk factors 
Smoking, raised blood pressure, raised serum cholesterol, and diabetes were established as 
risk factors in the development of CVDs by the Framingham Study and other early 
prospective studies in the USA and Europe (Figure 2).35-39. These observational studies 
motivated randomized trials of primary and secondary CVD prevention by lowering blood 
pressure and lipids, starting in the late 1960s (Figure 2). Randomized trials confirmed the 
causal roles of both blood pressure and serum cholesterol as risk factors for IHD and stroke, 
although the association of serum cholesterol with stroke has been found to be weaker than 
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that of blood pressure.40-43 After accounting for regression dilution bias due to imprecision of 
exposure measurement in observational data, effect sizes from prospective cohorts are 
consistent with those from trials for these two risk factors.44, 45  
 
Although there is limited trial data for smoking, its association with CVDs in observational 
studies has been robust in repeated re-analyses and after adjustments for other factors.46, 47 
Further, it is now established that secondhand smoke is a risk factor for CVDs. Exposure to 
secondhand smoke is common in many parts of the world, and has been included in recent 
global analyses.13 
 
The evidence on the CVD effects of diabetes and raised glucose has been more mixed. 
Despite strong associations between diabetes or high glucose levels and CVDs in 
observational studies, glucose lowering, especially through drug treatment, has not 
consistently resulted in the anticipated reductions in CVD events.48 The inconsistency 
between observational and trial data may be because of a number of reasons.49-51  First, most 
trials compared more vs. less intensive glucose lowering and did not have a true placebo 
group. Second, most diabetes treatment trials had short follow-up, and these conflicting 
results may indicate a trade-off between the benefits of long-term good glycemic control for 
CVD outcomes, and the risks of acute hypoglycemia, especially in patients with advanced 
diabetes or prior CVD history. Third, glucose lowering treatments tested in trials might have 
been partially ineffective or they may have resulted in unexpected, and harmful, pleiotropic 
effects on other CVD risk factors. Finally, diabetes may affect CVD risk through deleterious 
disease pathways other than high glucose levels that are not targeted by current glucose 
lowering medications. Nonetheless, the inconsistency between observational and clinical trial 
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evidence suggests that the magnitude of the association between high glucose and CVD is 
less reliable than those of blood pressure and lipids. 
 
Causal effects of adiposity 
Studies on adiposity as a risk factor for CVDs began in the 1950s.52, 53 Different studies have 
used different measures of adiposity including relative weight, skinfold, BMI, and more 
recently waist circumference and waist-to-hip ratio.54, 55 A systematic review of 
epidemiological studies that had used BMI as well as waist circumference and/or waist-to-hip 
ratio found that taken together, these studies do not show that any of the measures of 
adiposity had “superior discriminatory capability” in terms of risk of adverse cardiometabolic 
outcomes; any observed difference was “too small to be of any clinical relevance”.56 
Therefore, we focus on BMI in this review because there are substantially more population-
based data on BMI than other measures of adiposity in different countries.57, 58 
 
There is consistent evidence from observational studies that high BMI is associated with 
increased risk of CVDs, but the limited trial evidence to date has been primarily negative.59 
Weight management and weight loss, sometimes together with other dietary and lifestyle 
changes, have resulted in lower levels of blood pressure and lipids, and delayed incidence of 
diabetes, which are all established CVD risk factors.59-62 Also, observational data have shown 
that bariatric surgery is associated with favorable cardiovascular risk factor changes and 
lower incidence of cardiovascular events.63, 64 Further, Mendelian randomization studies 
support a causal link of high BMI with CVD risk.65-67 Nonetheless, like elevated glucose, the 
effect sizes used for global analyses are based on weaker evidence than those for raised blood 
pressure, serum cholesterol, and smoking.  
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Global epidemiology of established risk factors and BMI  
After the initial cohort studies, multi-country studies examined established CVD risk factors 
and high BMI in more diverse populations – e.g., the Seven Countries Study, and more 
recently the case-control Interheart and Interstroke studies and the Prospective Urban Rural 
Epidemiology (PURE) cohort study. Further, the MONICA Project investigated whether 
changes in these risk factors are associated with changes in IHD incidence and mortality at 
the population level.3, 68, 69  
 
Prospective cohorts were established in East Asia soon after those in western countries. In 
other regions, such as Africa, CVD risk factors were first studied in cross-sectional studies,70 
while  prospective cohorts largely began in the 1970s.71 There is now an abundance of 
prospective cohorts studying CVD risk factors in most regions, although many of these 
cohorts are small.  
 
More recently, researchers have pooled cohorts and trials in western and Asian populations.34, 
40, 72, 73 There are no cohort pooling studies in Latin America and Africa. The large sample 
sizes in these pooling studies has allowed quantifying the associations of established risk 
factors with CVDs not only by age group and sex, but also by ethnicity and/or region. The 
regional cohort pooling studies have shown that the relative risks for the effects of established 
risk factors on CVDs are similar between Asian and western populations (Table 1).34, 40, 74 
For smoking, variations in duration and intensity across the world lead to different 
magnitudes of association with CVDs. For this reason, analyses of CVDs attributable to 
smoking have had to find proxies that account for factors like smoking duration and 
intensity.6, 10, 75 
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Global and regional exposures 
How established CVD risk factors and high BMI vary across countries is complex and their 
levels are only partly associated with countries’ income and urbanization.76 BMI levels are 
highest in middle-income countries including in the Pacific island nations, Middle East and 
north Africa, parts of Latin America and Caribbean, and, for women, southern Africa (Figure 
3); BMI is still relatively low in central and east Africa, and south Asia.57, 58, 80 Regional 
mean BMIs in 2014 for men ranged from 21·4 kg/m² in central Africa and south Asia to 29·2 
kg/m² (95% credible interval 28·6–29·8) in Polynesia and Micronesia; for women the range 
was from 21·8 kg/m² (21·4–22·3) in south Asia to 32·2 kg/m² (31·5–32·8) in Polynesia and 
Micronesia.81 Among high-income countries, BMI is higher in native English-speaking 
countries than those in Asia and continental Europe. Diabetes prevalence is also highest in 
most of the same regions with high mean BMI.79, 82 For example, age-standardized diabetes 
prevalence in 2014 was higher than 20% in adult men and women in Polynesia and 
Micronesia, and around 15% in Melanesia and in the Middle East and north Africa.79 
Diabetes prevalence is higher than expected based on BMI in south Asia, and lower than 
expected based on BMI in northwestern Europe.79, 82  
 
Blood pressure is currently highest in sub-Saharan Africa, central and eastern Europe, and 
central Asia; it is generally lower in high income countries where it has been declining for 
decades.78 Total cholesterol is the only risk factor which follows a clear western risk model; it 
is high (although decreasing) in Europe, Australasia, and north America, and it is rising (from 
low levels) in east Asian countries such as Japan, China, and Thailand.77 Smoking, whose 
prevalence depends on both social norms and tobacco control policies, is highest among men 
in many parts of Asia and central and eastern Europe.83, 84 Among women, it is higher in 
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Europe than in other regions, with male and female smoking prevalences having become 
virtually the same in some European countries.   
 
Global and regional CVD effects 
The established risk factors and high BMI are collectively responsible for an estimated 9.7 
million annual CVD deaths in the world, after accounting for multi-causality and for 
mediation of the effects of high BMI by blood pressure, total cholesterol, and glucose 
(Figure 4).14, 34 3.9 million of these deaths are between 30 and 70 years of age, and hence are 
considered premature, and the remaining above 70 years of age. The majority of the risk-
factor-attributable CVD deaths result from elevated blood pressure, followed by smoking for 
men and by high BMI for women who, as noted above, smoke less than men in most regions. 
The largest number of deaths attributable to the established risk factors and high BMI, 
especially those attributable to high blood pressure, occurred in east Asia followed by the 
region of central and eastern Europe and central Asia. In high-income countries, 24% of 
deaths attributable to these five risks occur below 70 years of age, and the other 76% in 
people aged 70 years and older. The shares are 43% and 57%, respectively, in low- and 
middle-income countries. A higher proportion of deaths attributable to established risk factors 
are premature in low- and middle-income countries than in high-income countries for two 
reasons. First, a larger share of the population is younger than 70 years of age in the former 
group (96%) than in the latter (89%). Second, high-income countries have been successful in 
shifting CVD and high BMI to older ages, compared to low- and middle-income countries (a 
similar shift has been recorded for morbidity, a phenomenon known as compression of 
morbidity).85 
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Age-standardized CVD death rates attributable to the established risk factors plus high BMI 
were lowest in high-income countries, followed by Latin America and the Caribbean; they 
were highest in central and eastern Europe and central Asia, about four times that of high-
income countries (Figure 5). The CVD death rates attributable to established risk factors and 
high BMI are lowest in high-income countries because they experience the lowest levels of 
CVD mortality in the world,3, 4 and the levels of most CVD risk factors are low compared 
with low- and middle-income countries.14 In contrast, CVD death rates in central and eastern 
Europe and central Asia are highest in the world, and the levels of established risk factors and 
high BMI are also high in these regions, together leading to a large absolute CVD burden 
attributable to risk factor exposures. 
 
Alcohol use 
Causal effects of alcohol use 
Many observational studies have reported that compared with non-drinkers, light to moderate 
drinking is associated with a reduced risk of some CVDs and diabetes, although some debate 
remains about whether light or moderate drinking is truly cardioprotective.86-89 Mendelian 
randomization, using genetic variants involved in alcohol metabolism as proxies for lifelong 
differences in alcohol consumption, also supports a causal association between all levels of 
alcohol intake and IHD and stroke.90 Heavy drinking, especially when done in binge drinking 
episodes, is associated with increased risk of IHD, stroke and atrial fibrillation.87, 89, 91-93  
 
Global and regional exposures and CVD effects 
Per-capita alcohol consumption among adults ranges from close to zero in Pakistan and some 
countries in the Middle East and north Africa to > 15 liters of pure alcohol per adult per year 
in Belarus, Moldova, and Russia, largely from spirits.94 The prevalence of heavy episodic 
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drinking is > 30% among men and women combined (and ~50% among men) in some parts 
of Europe; it is >20% in some countries in sub-Saharan Africa and in Latin America and 
Caribbean.94 
 
Due to variations in both amount of alcohol consumed and patterns of consumption, the 
burden of alcohol use varies a great deal around the world; among different medical causes of 
death, the variation is largest for CVDs (as well as injuries).13, 94 In particular, the rise in 
harmful alcohol use in Russia and some other former soviet republics due to extensive post-
soviet social and political changes has led to a massive burden of CVDs attributable to 
alcohol in eastern Europe. Of the nearly 1 million CVD deaths attributable to alcohol use in 
the world, one half occur in central and eastern Europe and central Asia.13 The CVD burden 
of alcohol use in this region arises from the combination of having the world’s highest level 
of per-capita consumption and high prevalence of heavy episodic drinking.94 
 
Diet  
Causal effects of dietary risks 
The number of dietary factors included in global risk factor analyses in relation to CVD 
outcomes has increased from one (inadequate intake of fruits and vegetables) in the original 
CRA Study in 2000, to 11 in recent analyses (diet low in fruits, vegetables, wholegrains, nuts 
and seeds, fiber, and polyunsaturated and omega 3 fatty acids from seafood; diet high in 
processed meat, trans fats, and salt) (three other dietary factors included in recent CRA 
analyses, namely diets low in milk and calcium and high in red meat, were associated with 
cancers but not CVDs).9, 13 This increase in the number is partly driven by the increasing 
number of epidemiological studies on associations between various food groups, nutrients, 
and dietary patterns and CVDs.95 Most of the food groups in recent CRA analyses have good 
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observational evidence in relation to increased risk of CVD, including low intakes of 
vegetables and fruits,96, 97 nuts and seeds,98 whole grains,99 fiber, and fish;100 and high intakes 
of processed meat,101 trans fats,102 sugar-sweetened beverages and other highly processed 
carbohydrates,95, and salt.103 However, these diet-CVD associations tend to be affected by 
multiplicity of comparisons, high correlation among various components of diet, systematic 
and random measurement errors, and often selective reporting. The limitations impede robust 
elucidation of the presence and magnitudes of causal associations, perhaps even more so than 
those of BMI and blood glucose.23, 104 
 
Randomization is increasingly used to assess the effects of dietary factors on clinical CVD 
outcomes. Yet, owing to the difficulties of dietary trials, even some large trials, such as the 
Lyon Diet Heart Study and the Primary Prevention of Cardiovascular Disease with a 
Mediterranean Diet,105, 106 are affected by poor compliance and poorly defined comparator 
diets, early termination, and low event rates. These limitations could lead to imprecise and 
possibly biased effect estimates, and hence undermine robust quantification of the CVD 
burden of these factors. Nonetheless, the distinction between true causal and confounded 
associations is being sought out in an increasing number of well-designed randomized trials. 
For example, a number of well-designed trials have demonstrated the CVD benefits of 
replacing saturated fats with unsaturated fats.107, 108 In contrast, for fish oil, trials have 
collectively found null effects109. For salt intake, there is evidence from trials for adverse 
effects on blood pressure, i.e. higher salt intake is associated with higher blood pressure.110 
The blood pressure benefits of lower salt intake continue to levels that are below the currently 
recommended amounts.111 Evidence for increased risk of CVD events and deaths associated 
with high salt intake, however, come from prospective studies, which are affected by 
limitations related to exposure measurement and reverse causation.112 As a result, there is 
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broad agreement about the CVD harms of high levels of salt use but debate continues about 
the optimal low levels of consumption.113  
 
Global and regional CVD effects 
Global analyses have attributed millions of deaths from CVDs to various dietary factors – 
with the largest being due to low intake of fruits (4.3 million CVD deaths), nuts and seeds 
(2.5 million CVD deaths), whole grains (1.7 million CVD deaths), vegetables (1.7 million 
CVD deaths), and high salt intake (2.9 million CVD deaths).13 These figures are of the same 
magnitude as, or larger than, the effects of high BMI, blood glucose, and serum cholesterol. It 
is however important to note that various dietary traits can be correlated either due to 
behavioral and socioeconomic factors – i.e., preference for or affordability of more or less 
healthy foods – or because some foods simply substitute others. For example, eating more 
whole grains, unsaturated fats, and fresh fruits and vegetables may imply eating less 
processed carbohydrates, saturated fats and meat.114 Therefore the effects of different dietary 
factors are not additive, not only because of their etiological overlaps (which affects all risk 
factors) but also because of the potential for substitution.  
 
In terms of regional variations, fruit consumption in most regions is much lower than the 300 
grams/day used as the counterfactual (optimal) level in global analyses.13 Fruit consumption 
may be low because fruits are only available seasonally in many countries or have high prices 
relative to local purchasing power. Salt intake levels are high in most regions of the world, 
and particularly in central and east Asia and in eastern Europe.115-118 Trans fats intake is high 
in parts of the Middle East and north Africa, north America, and south Asia, whereas 
saturated fats are highest in the Pacific Islands, countries in southeast Asia where palm oil is 
used for cooking, and some central, eastern, and northern European countries.119  
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Physical inactivity  
Causal effects of physical inactivity 
The association between sedentary life styles or low physical activity and the risk of CVDs is 
largely based on observational studies, and hence may be affected by the same sources of 
error and bias as those discussed for diet and BMI. Nonetheless, the associations have been 
largely consistent since the early studies in the 1950s.120-122 The benefits of additional activity 
seem larger at low baseline activity levels than among people who are currently active 
indicating a non-linear dose-response relationship.123, 124 Meta-analysis of clinical trials also 
shows that medically prescribed and supervised exercise can reduce mortality rates of persons 
with pre-existing coronary artery disease.125  
 
Whilst the early evidence on this relationship was from studies of occupational activity, the 
great majority of studies since the 1980’s have been based on leisure time activity, which is 
important in industrialized societies. Leisure time activity has limited relevance to countries 
where most energy expenditure occurs during transportation by walking and cycling, and 
paid and domestic work.126, 127 The role of activity in domains other than leisure means that 
measuring the extent of physical inactivity in countries with diverse patterns of daily activity 
remains a major challenge.128 Further, the findings on the association between occupational 
physical activity and CVDs have been inconsistent, in particular regarding heavy 
occupational physical activity which has been associated with increased CVD risk.129 If the 
adverse effect of heavy occupational activity is confirmed in additional studies, there will a 
need for more emphasis on the domain (and perhaps social circumstances) of activity in 
public health recommendations and surveillance. 
 
 18 
Global and regional CVD effects 
Worldwide 2.5 million CVD deaths have been attributed to physical inactivity and 
insufficient activity.13 Inactivity is particularly prevalent, and its CVD burden is largest, in 
high-income countries, Middle East and north Africa, parts of Latin America, and Pacific 
islands.13 
 
Environmental risk factors 
A few environmental exposures associated with CVDs have been included in global CRA 
analyses, including exposure to lead and to pollutants in the ambient air and from household 
burning of biomass and coal for cooking and heating.9, 13  
 
Ambient air pollution 
Short- and long-term exposures to many pollutants in the ambient air have been associated 
with increased incidence, morbidity and mortality from CVDs.130 Particulate matter (PM), 
especially fine PM (PM2.5), has so far been used as the proxy marker for the hazardous 
effects of air pollution in global analyses.13, 131-134 PM2.5 concentrations in ambient air have 
been associated with increased risk of IHD and stroke (as well as heart failure which is a 
sequelae of a number of CVDs).130  
 
The effect sizes for PM-CVD association are smaller than those of smoking and the other 
established factors, and may be affected by residual confounding. More importantly, the great 
majority of prospective cohort studies on air pollution as a CVD risk factor are from Europe 
and north America,134 where concentrations are much lower than those in east and south Asia 
(Figure 6). Therefore, there is little data on concentration-response relationships at high 
pollution levels, typical of many Asian cities. The absence of direct studies has necessitated 
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extrapolating the concentration-response relationships beyond the levels measured in 
epidemiological studies.134 The estimated global and regional CVD burdens of air pollution 
are highly sensitive to how this extrapolation is done.133, 134 Further, PM in different parts of 
the world is emitted by different sources – including vehicle and industrial emissions, 
residential coal and biomass burning, crustal dust, and even sea salt.136, 137 There is growing 
evidence that the health effects of PM depend on its source and chemical composition.138, 139. 
Therefore, we should expect differences in toxicity across the world, which is not reflected in 
current estimates. 
 
With all of these assumptions and knowledge gaps taken into consideration, ambient PM was 
estimated to be responsible for nearly 2.5 million CVD deaths in the world in 2010. Over 
900,000 of these deaths occurred in east Asia and another 560,000 in south Asia.13 PM levels 
in these regions are substantially higher than in other regions, not only in cities but also 
spreading to rural areas (Figure 6). 
 
Household air pollution 
There are no direct studies of household air pollution from burning of biomass and coal as a 
risk factor for CVDs. Nonetheless, tens of studies have shown that household PM 
concentrations are the same or substantially higher than those in the ambient air. Therefore, 
global analyses have applied the same concentration-response as for ambient PM to 
household air pollution. Attributing some CVD burden to household air pollution is 
supported by the emerging evidence about its effect on blood pressure, and more recently on 
markers of inflammation.140, 141 In 2010, an estimated 2.1 million CVD deaths were 
attributable to household air pollution; over 1.3 million of these deaths occurred in east Asia 
and south Asia.142, 143 
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Lead exposure 
Long-term exposure to lead, measured as bone lead level, has been associated with raised 
blood pressure as well as with clinical CVD outcomes.144, 145 In high-income countries, 
leaded fuel and many other sources of lead exposure have been eliminated for decades.146 
Phasing out leaded fuel began much later in many low- and middle-income countries, and 
other sources such as battery recycling, paint, and lead-glazed ceramics, persist.146 
Populations in Middle East and north Africa, central and south America, and south Asia have 
some of the highest bone or blood lead concentrations.146 In 2010, accumulated life-course 
exposure to lead was estimated to be responsible for over 650,000 CVD deaths in the world.13 
 
Other environmental risk factors 
CVDs have also been associated, with varying degrees of evidence, with a number of other 
environmental factors which have so far not been quantified in global analyses because 
global exposure data are very limited. These risks include noise, cold and warm temperatures, 
and chemicals such as cadmium and arsenic.  
 
Noise from road traffic and aircraft has been associated with increased risk of IHD and 
hypertension.147-149 There is little data on population noise exposure other than in some high-
income countries.150 Such data, through measurement and modeling studies, are needed to 
quantify the burden of CVDs and other diseases attributable to noise. Noise exposure is likely 
to increase with urbanization and increased vehicle and airplane traffic, which will in turn 
increase its significance as a global CVD risk factor.  
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Both high and low temperatures are associated with increased risk of CVDs, although the 
temperatures at which the hazardous effects begin may depend on the overall annual and 
seasonal average temperatures.151-153 For mid- to high-latitude populations, the overall effect 
of low temperatures predominates over that of heat.153, 154 Therefore, although projected 
increases in weather variability due to global environmental change are expected to affect 
CVDs, the consequences will depend on the relative impacts of cold vs. warm temperatures 
and adaptation measures for each of them. These effects might be particularly relevant to 
low- and middle-income countries where there is less access to potential modifiers of risks 
from extreme temperatures such as quality housing, air conditioning and central heating. 
 
Emerging risk factors and omic markers 
The so-called emerging risk factors are biomarkers beyond the established risk factors 
identified in the early epidemiological studies in Figure 2. Although emerging risks have so 
far not been included in global analyses, rapidly-increasing epidemiological research on their 
role as CVD risk factors will inevitably raise a question on whether they should be included 
alongside other physiological factors.  
 
Despite intensive research, the evidence for consistent associations independent of the 
established risk factors is available for very few of these biomarkers.22  Further, their CVD 
effect sizes are small to modest, and many of them are affected by large heterogeneity and 
likely bias.22 Emerging risk factors with more consistent evidence include non-HDL 
cholesterol, serum albumin, apolipoprotein B/A1 ratio, glycosylated hemoglobin, lipoprotein-
associated phospholipase mass and activity, and nonfasting insulin. Of emerging risk factors, 
only IL-6 and Lp(a) have evidence from Mendelian randomization studies for a causative 
association.155, 156  
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Recently interest has also turned to omic technologies as a means of identifying new 
biomarkers, including genomic, metabolomic and epigenomic markers, for CVDs and their 
risk factors. Genome-wide association studies (GWAS) have to date identified tens of 
independent genetic variants associated significantly or suggestively with IHD in European 
and South Asian populations, with similar magnitudes of associations.157, 158. Despite these 
findings, the inclusion of genetic risk scores has not improved individual prediction of 
disease risk over and above established risk factors.159 At the population level, worldwide 
differences in CVDs are likely to be mainly due to the effects of behavioral, dietary and 
environmental exposures, healthcare access and quality, and possibly fetal and early life 
nutrition and environment.4, 11, 160-162 
 
Metabolomic profiling, and the identified metabolites, provide a potentially-comprehensive 
assessment of gene actions, intrinsic metabolism, and exposure to risk factors, which can 
collectively affect CVDs (or their physiological risks like blood pressure, diabetes and 
adiposity).163-166 Similarly, variations in DNA methylation at specific loci have also been 
associated with adiposity and diabetes.167, 168 However, similar to emerging risk factors, novel 
omic markers have not improved CVD risk prediction beyond the established risk factors, 
and, excepting the GWAS findings, evidence that they are on the casual pathway is either 
absent or limited.104, 169, 170 There are however promising new leads, for example evidence for 
a gut microbial step in choline metabolism related to atherosclerosis.171 Measurement of omic 
markers is still relatively specialized and expensive. Therefore, measuring them in worldwide 
population-based health surveys is for the time being unlikely and their application to CVDs 
currently remains in a research context for understanding disease mechanisms and identifying 
new biomarkers of risk factor exposure or therapeutic targets.   
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Future benefits of reducing major CVD risk factors and the global NCD target 
Following the establishment of the global targets for NCDs and their major risk factors, there 
is a need to estimate how much of future CVD mortality may be avoided if risk factor levels 
were reduced according to their global targets.5 The future benefits of risk factor prevention 
depend on two epidemiological characteristics of CVDs (and other NCDs). First, as seen in 
Figure 1, CVDs have multiple causes, combined effects from which lead to a particular 
disease rate in the population. Some of these causes are currently non-modifiable (e.g., 
genetic determinants), unmeasured or poorly measured (e.g., health-care quality or stress), or 
even unknown. Therefore, trends for CVDs can be different from that of any single risk 
factor or small number of risk factors, depending on how the other determinants and medical 
treatment are changing, and latency of effects.3 For example, CVD mortality in high-income 
countries has decreased for decades, during which time some of its risk factors (e.g., blood 
pressure, serum cholesterol, and, in some countries, smoking) have decreased and others 
(e.g., obesity and smoking in other countries) have increased.3, 160 The second characteristic 
of CVDs is that when exposure to one of its risk factors increases or decreases, the harmful or 
beneficial impacts on disease risk begin immediately and continue to accumulate gradually 
until risk reaches the levels of those who have had the higher/lower exposure over a 
prolonged period (see Table S1).3, 172, 173  Although the process may take up to 10 years of 
more,3, 172, 173 the reversibility of risk after exposure removal seems to occur more steeply 
than the accumulation of hazardous effect.3  This asymmetry of rapid benefits vs. more 
gradual harms may exist because although the development of atherosclerotic plaques or 
hardening of the arteries is gradual, the risk of a fatal obstruction of the coronary arteries 
might be reduced fairly quickly, particularly if a risk factor affects late-stage factors, such as 
clotting and thrombus formation.  
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It has been projected that if current trends continue, premature CVD mortality (defined as the 
probability of dying between 30 and 70 years of age from a CVD cause) will continue to 
decrease in the world as a whole, from 0.101 in 2010 to 0.083 in 2025, i.e., an 18% decrease 
which is less than the 25% global target (Figure 7).5 High-income countries, which currently 
have lower CVD death rates than other parts of the world, are projected to have a 29% 
reduction under current trends.   
 
After accounting for overlaps in the effects of risk factors and the gradual changes in CVD 
death rates following changes in population exposure, it is projected that the premature CVD 
mortality will further fall to 34% if targets for six of the seven risk factors with global targets 
(tobacco smoking, alcohol use, raised blood pressure and glucose, obesity and salt intake) are 
met (Table S2). The effects of risk factor targets on the projected course of CVD mortality in 
high-income countries is relatively small because high-income countries are already 
benefiting from mostly favorable risk factor trends, due to decreases in blood pressure, 
tobacco smoking, and alcohol use (as well as cholesterol for which there is no global target) 
although these favorable trends are partially offset by rising obesity and diabetes. Despite the 
projected decline in CVD death rates, the number of CVD deaths in high-income countries as 
a whole is projected to rise by a modest 0.2 million between 2010 and 2025, due to 
population growth and ageing (this increase the net effect of increase in number of deaths in 
some countries and decrease in others). Achieving the risk factor targets will help compensate 
for these demographic factors, and reduce the number of CVD deaths in high-income 
countries in 2025 to being the same as their 2010 levels. 
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Premature CVD mortality has also been declining in low- and middle-income countries as a 
whole (although rising in some regions)173 and is projected to continue this decline, with 
probability of dying from CVDs between 30 and 70 years of age declining from 0.118 in 
2010 to 0.095 in 2025 (Figure 7). This 20% decline is not enough to meet the global target. 
Further, population growth and ageing means that the number of CVD deaths in 2025 is 
expected to rise by 4.4 million compared to 2010. Achieving the risk factor targets will 
accelerate the decline in CVDs, leading to a 37% decline, achieve the global target, and avoid 
3.5 million deaths in 2025 alone. 
 
Limitations of current data on the health effects of CVD risk factors 
As described throughout this review, the estimated CVD burden of many risk factors is 
affected by the fact that limited data are available regarding population exposure and by 
likely or potential biases in the magnitudes of their effects. To overcome the limitations of 
data on population exposure, researchers have used sophisticated statistical methods for 
pooling worldwide population-based surveys,174 or proxy measures of risk factors exposure, 
e.g., lung cancer death rates as a measure of cumulative life-long smoking and satellite-based 
measurement as a proxy for ambient PM pollution.6, 175 Nonetheless, the estimated exposures 
have moderate-to-large uncertainties, even for a risk factor such as diabetes that is commonly 
used in clinical settings.79, 81 Further, small effect sizes and publication and reporting bias can 
undermine the presumed causal associations; even when causality is accepted, these 
limitations lead to bias in the magnitudes of associations.104  
 
The estimated CVD burden of risk factors is relatively robust to these issues for those risks 
with high prevalence and large causal effects (Figure 8), a situation that for CVD risks may 
be limited to high blood pressure, high cholesterol (for effects on IHD), smoking (among 
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men), and possibly harmful alcohol use (among Eastern European men). If causal effects are 
large but risk factor exposure is low, for example in the case of smoking in Asian and African 
women, the estimated health burden is most sensitive to the quality of, and error in, exposure 
data. The most common situation for CVD risks, however, is one of small effect sizes and 
high exposure levels, which applies to most dietary and environmental risks, physical 
inactivity, and high BMI and glucose. The estimated CVD burden of such high-exposure-
and-low-effect-size risks is highly sensitive to bias and residual confounding in their effect 
sizes. At the extreme, the real estimated CVD burden of such risks can be zero if the causal 
association is spurious. More likely, the CVD burden may be overestimated by many folds 
because inadequate adjustment and publication bias often lead to inflated effect sizes.104 The 
proportional overestimation of the CVD burden in the presence of bias and confounding is 
more severe in the case of small effect estimates. For illustration, if one half of the excess 
relative risk is due to residual confounding, and if the observed relative risk is 1.02, the CVD 
burden would be overestimated by 98% for those risks with universal exposure. The 
overestimation would be 67% if the observed relative risk is 1.50 and 50% if it is 2.0. 
 
Further, the CVD burden of risk factors is estimated by comparing their actual levels in 
worldwide populations with some counterfactual optimal level.9 Putting aside risks such as 
smoking, dietary trans fats, and binge drinking for which the optimal level in a population is 
unequivocally zero, the exposures used as counterfactual optimal levels in global analyses – 
e.g., a systolic blood pressure of 110-115 mmHg, BMI of 21-23 kg/m2, vigorous levels of 
physical activity for the whole population, and a daily fruit intake of 300 grams – 13 tend to 
be at the extreme levels in most epidemiological studies and hence are uncertain.  
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Finally, the effect sizes for the associations between risk factors and CVDs tend to attenuate 
with age, with relative risks approaching 1.0 in older ages.40 Because most epidemiological 
studies do not enroll a sufficiently large number of older individuals to robustly estimate 
small effects at these ages, relative risks in ages above 75 years either are not estimated or 
have large uncertainty. This gap in data has required extrapolating effect sizes to older ages 
for population-based analyses.13, 40 With CVD events and especially deaths increasingly 
shifting to older ages, this extrapolation increases the uncertainty of estimated CVD burden 
of risk factors. 
 
Conclusions 
Following the expansion of, and advances in, epidemiological research on the behavioral, 
dietary, environmental, and physiological causes of CVDs, the number of CVD risk factors in 
global CRA analyses has increased substantially, from a handful in 1990 to tens in recent 
analyses. The CRA analyses have attributed hundreds of thousands or millions of CVD 
deaths to the aforementioned risk factors. These numbers have in turn helped draw attention 
to important global or regional public health issues.  
 
The above-mentioned limitations and gaps in data on risk factor exposure and effect sizes 
should not overshadow the tremendous advances in understanding the causes of CVDs, and 
in measuring their levels in worldwide populations, since the first cohort studies were done 
five or six decades ago. Rather, they should motivate future efforts in collecting new data and 
re-analyzing existing ones that can improve our knowledge of the worldwide CVD effects of 
risk factors, as outlined in Table 2.  
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Even with these uncertainties a number of policies and interventions identified in Table 2, if 
successfully implemented, are likely to reduce the worldwide burden of CVDs through 
primordial prevention at the population level.176  Together with equitable access to high-
quality healthcare for CVD prevention and treatment, these actions can help replicate the 
successes of high-income countries in reducing CVD events and deaths, and to reduce global 
inequalities in CVD burden.3-5, 160, 176 
 
Finally, we note that CVDs and most of their risk factors are strongly inversely associated 
with individual and community socioeconomic status, as summarized in prior reviews.19, 160 
The higher CVD incidence and mortality in the poor is at least partly mediated by less 
favorable risk factor levels and more limited and lower quality healthcare for prevention and 
treatment,18, 160, 161 although independent pathways may also exist. Therefore all CVD 
prevention policies, and scientific analyses that inform them, should take into account their 
impacts on CVDs on the poor and on inequalities.160 
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Table 1. Comparison of the effect sizes (hazard ratios) for the associations of physiological 
risk factors with ischemic heart disease (IHD) and stroke between western and Asian cohorts. 
All effect sizes are shown at 65-74 years, because hazard ratios for CVDs attenuate with age. 
 
Risk factor Region Hazard ratio for 
IHD 
Hazard ratio for 
ischemic stroke 
Hazard ratio for 
hemorrhagic and 
other non-ischemic 
strokes 
Blood pressure (per 10 
mm Hg higher usual 
systolic blood 
pressure) 
Asian cohorts 1.37 (1.31-1.42) a 1.48 (1.42-1.54) a 1.51 (1.46-1.57) a 
Western cohorts 1.31 (1.30-1.33) b 1.42 (1.37-1.47) b 1.41 (1.37-1.45) b 
Serum cholesterol (per 
1 mmol/L higher usual 
total cholesterol) 
Asian cohorts 1.25 (1.21-1.29) a 1.10 (1.03-1.17) a No association 
Western cohorts 1.29 (1.26-1.33) b 1.06 (0.99-1.13) No association 
Fasting plasma 
glucose, FPG (per 1 
mmol/L higher usual 
or baseline FPG)  
Asian cohorts 1.24 (1.16-1.33) a 1.20 (1.10-1.31) a, d 
Western cohorts 1.13 (1.10-1.17) c 1.12 (1.07-1.18) c, d 
Body mass index, BMI 
(per 5 kg/m2 higher 
baseline BMI) 
Asian cohorts 1.32 (1.24-1.40) a 1.30 (1.19-1.42) a Not reported 
Western cohorts 1.36 (1.31-1.42) b 1.42 (1.32-1.52) b 1.58 (1.46-1.71) b 
a from re-analysis/overview of Asia-Pacific Cohort Studies Collaboration as reported by Singh et al.40 
b from re-analysis/overview of Prospective Studies Collaboration as reported by Singh et al.40 
c from re-analysis/overview of Emerging Risk Factor Collaboration as reported by Singh et al.40 
d Hazard ratios are for total stroke. 
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Table 2. Research, surveillance, and policy needs to better measure and reduce the 
cardiovascular disease (CVD) burden of preventable risk factors. 
 
Strategy Potential benefits 
Research 
Form regional and multi-region 
cohort pooling consortia  
Overcomes small sample sizes and unreliable and unstable effects in 
individual cohorts; partially overcomes publication bias that affects 
individual cohorts; allows estimates of effects by region, as has been done 
for established CVD risk factors in Asian and western cohorts.34, 40, 74   
Enroll older participants in 
epidemiological studies, and/or 
re-measure exposure among 
participants once they reach 70-
75 years  
Allows better estimation of the associations between risk factors and events 
in older ages, which is currently largely based on extrapolation,40 and 
having more robust age-specific effect sizes throughout the lifecourse. 
Develop methods and 
technologies (e.g., biomarkers 
and sensors) for better 
measurement of exposure to 
dietary and environmental CVD 
risks 
Helps with reducing error in exposures of interest and potential 
confounders in observational studies. 
Conduct randomized studies of 
dietary and environmental risks 
Establishes whether the observed associations are causal and provides 
unbiased estimates of the magnitude of causal effects. Such studies are 
however difficult and expensive for clinical CVD outcomes because they 
require several years of follow-up. The difficulties arise from the fact that 
in dietary trials, the intervention group may continue to consume at least 
some of their normal food and it may not be possible to blind intervention. 
Find ways to reduce selective 
reporting of positive findings in 
observational studies 
Investigate the practicality and impacts of registries of observational 
research where protocols would be registered, and/or requiring reporting of 
results together with those of the prior studies and formal assessment of 
publication bias.  
Surveillance 
Conduct periodic (e.g., every five 
years) population-based health 
examination surveys with 
measured data on risk factors; 
report data to the World Health 
Organization (WHO) 
Allows measuring risk factor levels and trends by age and sex, and possibly 
by other characteristics like rural and urban place of residence or 
socioeconomic status. Reporting to WHO, as done for mortality statistics, is 
needed for consistent global reporting.   
Use primary care (electronic) 
data as a source of risk factor 
exposure information 
Can be used in countries with universal health coverage and accessible 
primary care system, which includes many high-income countries (other 
than the United States) and several middle-income countries. Provides an 
efficient system for collecting annual data on risk factors which can be 
calibrated with periodic health examination surveys.  
Develop and deploy low-cost and 
low-power sensors for  
measurement of environmental 
CVD risks such as particulate 
matter and noise 
Allows measuring, and possibly real-time reporting, of environmental risks 
for CVDs with high spatial resolution.  
Policy a 
Eliminate or substantially reduce 
tobacco smoking and harmful 
alcohol use 
Will have substantial benefits for CVDs and other non-communicable 
diseases (NCDs). 
Eliminate manufactured trans 
fats; identify strategies to 
increase the intake of fresh fruits 
and vegetables, whole grains, and 
Will lower the burden of CVDs, diabetes, and some cancers. 
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unsaturated fats and reduce the 
intake of processed 
carbohydrates, excessive salt, and 
saturated fats  
Identify and treat, using 
combination of blood pressure 
and lipid lowering medicines and 
aspirin, people at high risk of 
CVDs, including those with a 
history of CVD event, with 
diabetes, and with high absolute 
risk b 
Will lower major physiological risks and the burden of CVDs. 
 
Develop and implement 
regulations, economic measures 
and technologies that promote the 
use of clean fuels for household 
cooking and heating and reduce 
ambient air pollution 
Will lower the burden of CVDs, other NCDs, and childhood diseases; 
improves quality of life. 
a See Ezzati and Riboli176 for further strategies for prevention of CVDs and others NCDs, and whether and 
where there are examples of successful implementation of these strategies. 
b Achieving this aim requires an equitable and high-quality primary care system and availability of essential, and 
typically low-cost, medicines for CVD prevention and early-stage treatment.4, 176, 177 In countries with limited 
healthcare infrastructure, the system may rely on non-physician health workers with appropriate training and 
guidelines. Examples of such programs have been implemented in some low- and middle-income countries for 
some CVD risk factors especially for diabetes.178, 179   
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Figure 1. Schematic diagram of the determinants of and risk factors for cardiovascular 
diseases. 
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Figure 2. Major milestones and studies of established and emerging cardiovascular disease 
risk factors. See http://www.epi.umn.edu/cvdepi/ for additional historical studies. 
 
 
  
 35 
Figure 3. Mean population body mass index (BMI), systolic blood pressure (SBP), and 
serum total cholesterol (TC), and prevalence of diabetes in different world regions. The 
estimates are from pooled analysis of hundreds of population based measurement studies, as 
described in detail elsewhere.58, 77-79 See www.ncdrisc.org for additional data and interactive 
visualizations. 
  
 36 
Figure 4. Deaths from cardiovascular diseases (CVDs) in people aged 30 years and older, 
attributable to the individual and combined effects of smoking and high body mass index 
(BMI), blood pressure and glucose and serum cholesterol by region and (A) sex and (B) age 
group, 1980–2010. Data sources and methods are described elsewhere.5, 14 In addition to 
CVDs, some of these risks are associated with increased risk of diabetes, chronic kidney 
disease, and cancers.13, 14 Deaths attributable to individual risk factors show their total CVD 
burden. Deaths attributable to the combined effects of all risk factors account for multi-
causality and for the partial mediation of the effects high BMI through high blood pressure 
and glucose and serum cholesterol.14, 34 
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Figure 5. Age-standardized cardiovascular death rates among people aged 30 years and older 
attributable to the combined effects of smoking and high body mass index, blood pressure 
and glucose and serum cholesterol by region and sex. Death rates were standardized to the 
World Health Organization standard population. 
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Figure 6. Average concentration of fine particulate matter (PM2.5) over a decade from 2001 
to 2010. Reproduced from van Donkelaar et al.135   
 
The high concentrations in central Asia and the Middle East and north Africa are largely due 
to crustal particulate matter (dust). 
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Figure 7. The impact of achieving globally-agreed targets for six risk factors (tobacco 
smoking, alcohol use, salt intake, obesity and raised blood pressure and glucose) on the 
probability of dying prematurely (A) and number of deaths (B) from cardiovascular diseases 
in high-income versus low- and middle-income countries. Source: re-analysis based on data 
and methods in Kontis et al.5 
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Figure 8. Population attributable fractions (PAFs) for different risk factor prevalences and 
effect sizes (relative risks, RR). For each RR, the graph shows PAF at different levels of risk 
factor prevalence. Differences and errors in prevalence can be characterized by movement 
along each curve, and those of effect size by moving from one curve to another. 
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